B
18.00
-0.17 (-0.94%)
| Previous Close | 18.17 |
| Open | 18.17 |
| Volume | 503,756 |
| Avg. Volume (3M) | 403,170 |
| Market Cap | 983,024,576 |
| Price / Book | 2.47 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2025 |
| Diluted EPS (TTM) | -1.69 |
| Total Debt/Equity (MRQ) | 0.13% |
| Current Ratio (MRQ) | 24.62 |
| Operating Cash Flow (TTM) | -88.27 M |
| Levered Free Cash Flow (TTM) | -53.72 M |
| Return on Assets (TTM) | -13.84% |
| Return on Equity (TTM) | -27.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Bicara Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
-0.4
| Analyst Consensus | -3.5 |
| Insider Activity | -1.5 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.40 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.65% |
| % Held by Institutions | 89.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Mizuho, 0.00%) | Hold |
| Median | 14.50 (-19.44%) | |
| Low | 11.00 (Wells Fargo, -38.89%) | Hold |
| Average | 14.50 (-19.44%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 16.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 18 Dec 2025 | 18.00 (0.00%) | Hold | 18.48 |
| Wells Fargo | 11 Nov 2025 | 11.00 (-38.89%) | Hold | 14.73 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COHLHEPP RYAN | - | 18.48 | -12,500 | -231,000 |
| Aggregate Net Quantity | -12,500 | |||
| Aggregate Net Value ($) | -231,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 18.48 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COHLHEPP RYAN | Officer | 15 Dec 2025 | Automatic sell (-) | 12,500 | 18.48 | 231,000 |
| COHLHEPP RYAN | Officer | 15 Dec 2025 | Option execute | 8,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |